Literature DB >> 25348135

Gene expression analyses to explore the biomarkers and therapeutic targets for gliomas.

Lina Wang1, Bo Wei, Guozhang Hu, Le Wang, Ying Jin, Zhigang Sun.   

Abstract

To improve treatment strategies of glioma, microarray data were applied to screen target molecules that were regulated by microRNAs (miRNAs). GSE31262 was downloaded from Gene Expression Omnibus, including five neural stem cells samples from normal human and nine stem cells samples from glioma patients. Differentially expressed genes (DEGs) were identified with Multtest package and Limma package of R language, and false discovery rate < 0.05 and |log2FC (fold change)| >1 were chosen as cut-off criterion. Hierarchical clustering and pathway enrichment analysis of DEGs were performed using pheatmap package of R language and KOBAS software, respectively. miRNAs related to up- and down-regulated DEGs were, respectively, predicted by WebGestalt software and its miRNAs-target DEGs interaction network were, respectively, constructed by STRING database. Bingo plug-in in Cytoscape software was applied to analyze Gene Ontology functional enrichment analysis for up- and down-regulated DEGs in network, respectively. A total of 428 DEGs were selected, including 331 down-regulated and 97 up-regulated DEGs. Hierarchical clustering analysis showed that glioma samples and normal samples were completely separated. Pathway analysis indicated that CDK2 and WEE1 participated in the cell cycle. miR-124 could simultaneously regulate up-regulated (ELAVL1 and EZH2) and down-regulated (BACE1) DEGs. The down-regulated genes (KIF23, WEE1 and CDK2) were associated with cell division, while the up-regulated genes (PLP1 and MBP) were related to myelination of neurons. miR-124 might participate in development of glioma by regulating BACE1, ELAVL1 and EZH2. The biomarkers (KIF23, WEE1, CDK2, PLP1 and MBP) were considered as therapeutic targets of glioma.

Entities:  

Mesh:

Year:  2014        PMID: 25348135     DOI: 10.1007/s10072-014-1985-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  29 in total

1.  The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing.

Authors:  Eugene V Makeyev; Jiangwen Zhang; Monica A Carrasco; Tom Maniatis
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

2.  DNA methylation silences miR-132 in prostate cancer.

Authors:  A Formosa; A M Lena; E K Markert; S Cortelli; R Miano; A Mauriello; N Croce; J Vandesompele; P Mestdagh; E Finazzi-Agrò; A J Levine; G Melino; S Bernardini; E Candi
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

3.  Characterization of the DNA-binding domains from the yeast cell-cycle transcription factors Mbp1 and Swi4.

Authors:  I A Taylor; P B McIntosh; P Pala; M K Treiber; S Howell; A N Lane; S J Smerdon
Journal:  Biochemistry       Date:  2000-04-11       Impact factor: 3.162

4.  The treatment of glioblastoma multiforme of the brain.

Authors:  R Jelsma; P C Bucy
Journal:  J Neurosurg       Date:  1967-11       Impact factor: 5.115

Review 5.  Genetics of adult glioma.

Authors:  McKinsey L Goodenberger; Robert B Jenkins
Journal:  Cancer Genet       Date:  2012-12-11

6.  Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.

Authors:  Ian F Pollack; Ronald L Hamilton; C David James; Sydney D Finkelstein; Judith Burnham; Allan J Yates; Emiko J Holmes; Tianni Zhou; Jonathan L Finlay
Journal:  J Neurosurg       Date:  2006-11       Impact factor: 5.115

7.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

Review 8.  Hereditary tumor syndromes and gliomas.

Authors:  David Reuss; Andreas von Deimling
Journal:  Recent Results Cancer Res       Date:  2009

9.  Cytoscape 2.8: new features for data integration and network visualization.

Authors:  Michael E Smoot; Keiichiro Ono; Johannes Ruscheinski; Peng-Liang Wang; Trey Ideker
Journal:  Bioinformatics       Date:  2010-12-12       Impact factor: 6.937

10.  Evaluating different methods of microarray data normalization.

Authors:  André Fujita; João Ricardo Sato; Leonardo de Oliveira Rodrigues; Carlos Eduardo Ferreira; Mari Cleide Sogayar
Journal:  BMC Bioinformatics       Date:  2006-10-23       Impact factor: 3.169

View more
  5 in total

Review 1.  The Transient Receptor Potential Vanilloid Type-2(TRPV2) Ion Channels in Neurogenesis andGliomagenesis: Cross-Talk between TranscriptionFactors and Signaling Molecules.

Authors:  Giorgio Santoni; Consuelo Amantini
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

2.  Distinct cognitive effects and underlying transcriptome changes upon inhibition of individual miRNAs in hippocampal neurons.

Authors:  Josephine Malmevik; Rebecca Petri; Pina Knauff; Per Ludvik Brattås; Malin Åkerblom; Johan Jakobsson
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

3.  Candidate genes and microRNAs for glioma pathogenesis and prognosis based on gene expression profiles.

Authors:  Chen Xie; Meng Xu; Dejuan Lu; Weiguang Zhang; Laizang Wang; Hongwei Wang; Jianhua Li; Fubin Ren; Chao Wang
Journal:  Mol Med Rep       Date:  2018-06-29       Impact factor: 2.952

4.  miR-30a-3p Targets MAD2L1 and Regulates Proliferation of Gastric Cancer Cells.

Authors:  Yu Wang; Fenghui Wang; Jing He; Juan Du; Huahua Zhang; Haiyan Shi; Yani Chen; Yameng Wei; Wanjuan Xue; Jing Yan; Yun Feng; Yi Gao; Dan Li; Jiming Han; Jing Zhang
Journal:  Onco Targets Ther       Date:  2019-12-19       Impact factor: 4.147

5.  Prognostic Value of Genes and Immune Infiltration in Prostate Tumor Microenvironment.

Authors:  Wenguo Sun; Hailin Shi; Zhen Yuan; Li Xia; Xuebao Xiang; Xiangfeng Quan; Wenjie Shi; Leiming Jiang
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.